Erasca Inc ERAS:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/03/24 EDT
2.14UNCH (UNCH)
Volume
6,396
Close
2.14UNCH (UNCH)
Volume
253,429
52 week range
1.51 - 3.38
Loading...
  • Open2.22
  • Day High2.23
  • Day Low2.11
  • Prev Close2.14
  • 52 Week High3.38
  • 52 Week High Date06/06/23
  • 52 Week Low1.51
  • 52 Week Low Date12/01/23

Key Stats

  • Market Cap370.945M
  • Shares Out173.34M
  • 10 Day Average Volume0.48M
  • Dividend-
  • Dividend Yield-
  • Beta1.1
  • YTD % Change0.47

KEY STATS

  • Open2.22
  • Day High2.23
  • Day Low2.11
  • Prev Close2.14
  • 52 Week High3.38
  • 52 Week High Date06/06/23
  • 52 Week Low1.51
  • 52 Week Low Date12/01/23
  • Market Cap370.945M
  • Shares Out173.34M
  • 10 Day Average Volume0.48M
  • Dividend-
  • Dividend Yield-
  • Beta1.1
  • YTD % Change0.47

RATIOS/PROFITABILITY

  • EPS (TTM)-0.83
  • P/E (TTM)-2.57
  • Fwd P/E (NTM)-2.46
  • EBITDA (TTM)-137.793M
  • ROE (TTM)-34.33%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/14/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Erasca Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline in the industry, which is focused on modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway;...
Jonathan Lim M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Nik Chetwyn Ph.D.
Chief Operating Officer
David Chacko M.D.
Chief Financial Officer and Chief Business Officer
Ebun Garner Esq.
General Counsel, Corporate Secretary
Address
10835 Road To The Cure, Suite 140
San Diego, CA
92121-1130
United States

Top Peers

SYMBOLLASTCHG%CHG
ATAI
ATAI Life Sciences NV
2.05UNCHUNCH
NAUT
Nautilus Biotechnology Inc
2.69UNCHUNCH
TERN
Terns Pharmaceuticals Inc
5.44UNCHUNCH
TNYA
Tenaya Therapeutics Inc
4.68UNCHUNCH
SLDB
Solid Biosciences Inc
10.10UNCHUNCH